Derivative

Form 8.3 - The Vanguard Group, Inc.: Xeris Pharmaceuticals, Inc

Retrieved on: 
Friday, June 18, 2021
Stock market, Financial law, Security, Derivative, Electronic voting, Finance, Articles, Human activities, Regulation S-K

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.

Key Points: 
  • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
  • If none, this should be stated.
  • Is a Supplemental Form 8 attached?
  • (Note 9) NO

Form 8.3 - The Vanguard Group, Inc.: Willis Towers Watson plc

Retrieved on: 
Friday, June 18, 2021
Stock market, Financial law, Security, Derivative, Electronic voting, Finance, Articles, Human activities, Regulation S-K

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.

Key Points: 
  • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
  • If none, this should be stated.
  • Is a Supplemental Form 8 attached?
  • (Note 9) NO

Form 8.3 - The Vanguard Group, Inc.: Strongbridge Biopharma plc

Retrieved on: 
Friday, June 18, 2021
Stock market, Financial law, Security, Derivative, Electronic voting, Finance, Articles, Human activities, Regulation S-K

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.

Key Points: 
  • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
  • If none, this should be stated.
  • Is a Supplemental Form 8 attached?
  • (Note 9) NO

Form 8.3 - The Vanguard Group, Inc.: UDG Healthcare plc

Retrieved on: 
Friday, June 18, 2021
Stock market, Financial law, Security, Derivative, Electronic voting, Finance, Articles, Human activities, Regulation S-K

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.

Key Points: 
  • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
  • If none, this should be stated.
  • Is a Supplemental Form 8 attached?
  • (Note 9) NO

Form 8.3 - The Vanguard Group, Inc.: Aon plc

Retrieved on: 
Friday, June 18, 2021
Stock market, Financial law, Security, Derivative, Electronic voting, Finance, Articles, Human activities, Regulation S-K

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.

Key Points: 
  • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
  • If none, this should be stated.
  • Is a Supplemental Form 8 attached?
  • (Note 9) NO

DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Churchill Capital Corp. IV and Encourages Investors to Contact the Firm

Retrieved on: 
Friday, June 18, 2021
Legal, Professional services, Stock market, Derivative, Financial law, Wagering, Security, Finance, Primary dealers, Investment, Subprime mortgage crisis

Investors have until June 18, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until June 18, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • On February 22, 2021, the merger between Churchill and Lucid was announced with transaction equity value estimated at $11.75 billion.
  • On February 23, 2021, Churchills stock fell $22.16, or 38%, to close at $35.21 per share on February 23, 2021.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Inland Bank and Trust Partners with Leading Global Advisory Firm Chatham Financial

Retrieved on: 
Thursday, June 17, 2021
Professional services, Technology, Other Technology, Finance, Consulting, Banking, Financial market, Finance, Derivative

Inland Bank and Trust (Inland Bank) recently partnered with leading global advisory and technology firm Chatham Financial (Chatham).

Key Points: 
  • Inland Bank and Trust (Inland Bank) recently partnered with leading global advisory and technology firm Chatham Financial (Chatham).
  • Chatham is the largest independent financial risk management firm in the United States with extensive expertise in the debt and derivatives markets.
  • This strategic partnership expands Inland Banks advisory capabilities and provides commercial borrowers customized finance solutions and competitive terms through interest rate swaps.
  • We look forward to working with Inland Bank to provide borrowers with tailored financing options and the necessary tools to succeed, said Matthew Tevis, Managing Partner of the Financial Institutions Practice at Chatham Financial.

PILOT BANCSHARES ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of PLBN and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, June 17, 2021
Corporate finance, Stock market, Finance, Money, Corporations, Security, Mergers and acquisitions, Derivative, Stock

On June 16, 2021, Pilot announced that it had signed an agreement to merge with Lake Michigan in an all-cash transaction.

Key Points: 
  • On June 16, 2021, Pilot announced that it had signed an agreement to merge with Lake Michigan in an all-cash transaction.
  • Pursuant to the merger agreement, Pilot stockholders will receive $6.25 in cash for each share of Pilot common stock owned.
  • Bragar Eagel & Squire is concerned that Pilots board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Form 8.3 - The Vanguard Group, Inc.: Willis Towers Watson plc

Retrieved on: 
Thursday, June 17, 2021
Stock market, Financial law, Security, Derivative, Electronic voting, Finance, Articles, Human activities, Regulation S-K

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.

Key Points: 
  • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
  • If none, this should be stated.
  • Is a Supplemental Form 8 attached?
  • (Note 9) NO

Form 8.3 - The Vanguard Group, Inc.: Xeris Pharmaceuticals, Inc

Retrieved on: 
Thursday, June 17, 2021
Stock market, Financial law, Security, Derivative, Electronic voting, Finance, Articles, Human activities, Regulation S-K

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.

Key Points: 
  • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
  • If none, this should be stated.
  • Is a Supplemental Form 8 attached?
  • (Note 9) NO